PDS Biotechnology (NASDAQ:PDSB) Downgraded to "Sell" Rating by StockNews.com

StockNews.com cut shares of PDS Biotechnology (NASDAQ:PDSB - Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the company. Alliance Global Partners upgraded PDS Biotechnology to a "strong-buy" rating in a research report on Wednesday, August 21st. HC Wainwright reiterated a "buy" rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $14.25.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock traded up $0.01 on Friday, hitting $3.29. The stock had a trading volume of 310,558 shares, compared to its average volume of 304,287. PDS Biotechnology has a 52-week low of $2.53 and a 52-week high of $6.85. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market cap of $121.14 million, a price-to-earnings ratio of -2.70 and a beta of 1.93. The company's 50 day moving average price is $3.25 and its 200 day moving average price is $3.28.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period last year, the firm posted ($0.37) earnings per share. On average, research analysts anticipate that PDS Biotechnology will post -1.24 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company's stock worth $6,288,000 after acquiring an additional 82,135 shares in the last quarter. Blair William & Co. IL lifted its stake in PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company's stock valued at $357,000 after buying an additional 81,743 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in PDS Biotechnology in the 2nd quarter valued at approximately $146,000. Squarepoint Ops LLC purchased a new stake in PDS Biotechnology in the 2nd quarter valued at approximately $120,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PDS Biotechnology during the 2nd quarter worth $115,000. Institutional investors and hedge funds own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.